Johnson and Johnson

26 sept. 2026, 00:01 UTC

Johnson & Johnson's TREMFYA® met endpoints in the Phase 4 STAR study, but the stock is trading lower in after-market hours amid routine fluctuations.

25 sept. 2026, 20:07 UTC

Johnson & Johnson's stock rose after positive Phase 4 STAR study results for Tremfya and encouraging long-term data for CARVYKTI in multiple myeloma patients.

24 sept. 2026, 23:01 UTC

Johnson & Johnson's shares are advancing in after-market trading, holding a roughly flat position since Thursday's close amid limited fluctuations.

23 sept. 2026, 23:05 UTC

Johnson & Johnson is experiencing a slight decline in after-market trading, reflecting a cumulative return near the lower end of its one-month trading range.

22 sept. 2026, 20:07 UTC

Johnson & Johnson shares fell following a slight decline from Monday's close, despite bullish social media sentiment and positive Phase 3 study results for CAPLYTA®.

21 sept. 2026, 20:06 UTC

Johnson & Johnson's stock is declining today despite receiving EU approval for ICOTYDE, a new treatment for plaque psoriasis, and positive Phase 3 results for Caplyta.

18 sept. 2026, 23:01 UTC

Johnson & Johnson's shares advanced modestly in after-market trading, continuing positive momentum following five consecutive sessions that ended higher.

17 sept. 2026, 23:06 UTC

Johnson & Johnson is trading slightly higher in after-market hours, continuing a trend of five consecutive sessions finishing higher since Thursday's close.

16 sept. 2026, 23:06 UTC

Johnson & Johnson's shares are trading lower in after-market hours, briefly dipping to a low while remaining below their 20-day moving average.

15 sept. 2026, 23:01 UTC

Johnson & Johnson shares are lower in after-market trading amid negative market sentiment following a sharp decline in the New York Empire State Manufacturing Index.

14 sept. 2026, 23:06 UTC

Johnson & Johnson shares rose in after-market trading following the final survival analysis results of the Phase 3 PAPILLON study for RYBREVANT and chemotherapy.

12 sept. 2026, 00:01 UTC

Johnson & Johnson shares rose in after-hours trading amid reports of Apollo Global Management discussing a $20 billion acquisition of its DePuy Synthes unit.

11 sept. 2026, 23:41 UTC

Johnson & Johnson shares higher after news of Apollo Global Management's interest in acquiring its $20 billion orthopedics unit, DePuy Synthes.

10 sept. 2026, 20:07 UTC

Johnson & Johnson shares are lower despite receiving CE Marking for its ACUVUE OASYS MAX 2-Week lens, with HSBC raising its price target to $320.

9 sept. 2026, 23:01 UTC

Johnson & Johnson shares are higher in after-market trading, reflecting a modest increase since Wednesday's close despite three consecutive sessions of declines.

8 sept. 2026, 20:02 UTC

Johnson & Johnson shares are lower today amid declines in the Pharmaceuticals sub-sector, despite strong merger and acquisition capacity estimated at $80 billion.

5 sept. 2026, 00:01 UTC

Johnson & Johnson shares are higher in after-market trading, with no specific news driving the move. The stock reached a session high earlier today.

4 sept. 2026, 20:08 UTC

Shares of Johnson & Johnson are lower as Timothy Schmid exercised stock options for 33,597 shares valued at approximately $4.39 million.

3 sept. 2026, 23:41 UTC

Johnson & Johnson's shares are lower in after-market trading following FDA approval of IMAAVY and a jury verdict in a talc case.

2 sept. 2026, 23:06 UTC

Johnson & Johnson will participate in the Deutsche Bank 2026 Healthcare Summit on September 17. Shares are higher in after-market trading following the announcement.

1 sept. 2026, 20:01 UTC

Johnson & Johnson shares are higher today, reaching the upper end of their one-month trading range during the session. No specific news was identified.

31 aug. 2026, 23:06 UTC

Johnson & Johnson shares are higher in after-market trading following the announcement of an investor conference call on October 13, 2026, for third-quarter results.

29 aug. 2026, 00:01 UTC

Johnson & Johnson shares higher in after-market trading following FDA approval of Stelara for pediatric ulcerative colitis treatment, expanding its market potential.

28 aug. 2026, 20:08 UTC

Johnson & Johnson shares are higher during Friday's session, reflecting a modest gain since Thursday's close amid routine trading and rising Treasury yields.

27 aug. 2026, 23:01 UTC

Johnson & Johnson shares advanced in after-market trading, recovering from earlier volatility. Broader market context includes a decline in initial jobless claims.

26 aug. 2026, 23:06 UTC

Johnson & Johnson shares are lower during after-market hours, reflecting a decline since Wednesday's close amid broader market concerns over persistent inflation pressures.

25 aug. 2026, 23:06 UTC

Johnson & Johnson shares are lower in after-market trading, reflecting broader market trends and a decline in crude oil prices influencing investor sentiment.

24 aug. 2026, 19:06 UTC

Johnson & Johnson's shares are higher today, recovering from earlier volatility and trading above its 20-day moving average near a one-month peak.

21 aug. 2026, 23:06 UTC

Johnson & Johnson shares are higher in after-hours trading, maintaining a position above the 20-day moving average despite a slight pullback from earlier gains.

20 aug. 2026, 23:41 UTC

Johnson & Johnson shares are higher in after-market trading following operational sales growth and a raised full-year outlook amid recent FDA clearances for its bronchoscopy software.